Journal of Gastroenterology

, Volume 52, Issue 4, pp 476–482

Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis

  • Atsushi Nishida
  • Hirotsugu Imaeda
  • Masashi Ohno
  • Osamu Inatomi
  • Shigeki Bamba
  • Mitsushige Sugimoto
  • Akira Andoh
Original Article—Alimentary Tract



The clinical utility of fecal microbiota transplantation (FMT) in patients with ulcerative colitis (UC) is still controversial. We investigated the efficacy and safety of single FMT for patients with mild to moderately active UC in a Japanese population.


Fifty-seven patients were evaluated for eligibility, and 16 patients were excluded. Forty-one patients with UC refractory to standard medical therapy were treated with single FMT by colonoscopic administration. Changes in the fecal microbiota were assessed by 16S ribosomal DNA based terminal restriction fragment length polymorphism analysis.


At 8 weeks after FMT, no patient achieved clinical remission, and 11 of 41 patients (26.8 %) showed clinical response. The full Mayo score and the Mayo clinical score significantly decreased at week 8 [full Mayo score 5.5 ± 2.4 (mean ± standard deviation) at initiation and 4.6 ± 2.2 at week 8, P < 0.004; Mayo clinical score 4.0 ± 2.0 at initiation and 3.0 ± 1.9 at week 8, P < 0.001], but there were no statistically significant effects on the Mayo endoscopic score. No adverse events occurred after FMT or during the follow-up period of 8 weeks. The proportion of Bifidobacterium was significantly higher in the donor feces used for responders than in the donor feces used for nonresponders. The proportion of Lactobacillales and Clostridium cluster IV were significantly higher in the donor feces used for nonresponders.


Single FMT by colonoscopy was performed safely in all patients, but sufficient clinical efficacy and microbial restoration were not confirmed in patients with mild to moderately active UC.


Ulcerative colitis Gut microbiota Colonoscopy 

Supplementary material

535_2016_1271_MOESM2_ESM.pptx (72 kb)
Changes of the fecal microbial structure after FMT. The fecal microbial composition was assessed by T-RFLP analysis, and the microbial structures of 4 representative patients and their donors are illustrated. W0 patient at screening, W8 patient at 8 weeks after FMT, D donor. (PPTX 72 kb)
535_2016_1271_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 18 kb)


  1. 1.
    Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. J Gastroenterol. 2015;50:495–507.CrossRefPubMedGoogle Scholar
  2. 2.
    Goldsmith JR, Sartor RB. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol. 2014;49:785–98.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489–99.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Li J, Butcher J, Mack D, et al. Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:139–53.CrossRefPubMedGoogle Scholar
  5. 5.
    Takahashi K, Nishida A, Fujimoto T, et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease. Digestion. 2016;93:59–65.CrossRefPubMedGoogle Scholar
  6. 6.
    Bernstein CN. Antibiotics, probiotics and prebiotics in IBD. Nestle Nutr Inst Workshop Ser. 2014;79:83–100.CrossRefPubMedGoogle Scholar
  7. 7.
    van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15.CrossRefPubMedGoogle Scholar
  8. 8.
    Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Sbahi H, Di Palma JA. Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders. BMJ Open Gastroenterol. 2016;3:e000087.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology. 2015;149:223–37.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102–9.e106.CrossRefPubMedGoogle Scholar
  12. 12.
    Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110–8.e114.CrossRefPubMedGoogle Scholar
  13. 13.
    Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:1569–81.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Nakayama J, Watanabe K, Jiang J, et al. Diversity in gut bacterial community of school-age children in Asia. Sci Rep. 2015;5:8397.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Nishijima S, Suda W, Oshima K, et al. The gut microbiome of healthy Japanese and its microbial and functional uniqueness. DNA Res. 2016;23:125–33.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Andoh A, Imaeda H, Aomatsu T, et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol. 2011;46:479–86.CrossRefPubMedGoogle Scholar
  17. 17.
    Nagashima K, Hisada T, Sato M, et al. Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol. 2003;69:1251–62.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One. 2013;8:e61217.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139:1844–54.e1.CrossRefPubMedGoogle Scholar
  20. 20.
    Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–83.CrossRefPubMedGoogle Scholar
  21. 21.
    Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2015. doi:10.1136/gutjnl-2015-309990.
  22. 22.
    Flint HJ, Scott KP, Louis P, et al. The role of the gut microbiota in nutrition and health. Nat Rev Gastrol Hepatol. 2012;9:577–89.CrossRefGoogle Scholar
  23. 23.
    Schwiertz A, Taras D, Schafer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18:190–5.CrossRefGoogle Scholar
  24. 24.
    Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731–6.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–4.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2016

Authors and Affiliations

  • Atsushi Nishida
    • 1
  • Hirotsugu Imaeda
    • 1
  • Masashi Ohno
    • 1
  • Osamu Inatomi
    • 1
  • Shigeki Bamba
    • 1
  • Mitsushige Sugimoto
    • 1
  • Akira Andoh
    • 1
  1. 1.Department of MedicineShiga University of Medical ScienceOtsuJapan

Personalised recommendations